What does Anlon Healthcare Ltd do?
Overview
Anlon Healthcare Limited is a research intensive manufacturer based in Rajkot, Gujarat, India specializing in pharmaceutical bulk drugs namely Active Pharmaceutical Ingredients (APIs) and Drug Intermediates – the essential building blocks used in the formulation of medicines. Their operations also extend into nutraceutical APIs, personal care, and animal health products. They serve not just domestic clients but have a growing global presence, exporting to over 15 countries including Italy, Germany, South Korea, Japan, Brazil and more.
Core Offerings & Capabilities:
1. APIs & Drug Intermediates
- They manufacture high purity APIs – the active components in prescription and over the counter medications.
- They also produce drug intermediates, which are critical precursors in API synthesis.
2. Compliance with Global Standards
- Their facilities adhere to international regulatory norms, including FDA, PMDA (Japan), KFDA, WHO GMP as well as pharmacopeia standards like IP, BP, EP, JP, USP.
3. Custom Manufacturing and R&D Focus
- Anlon offers custom synthesis for complex chemical compounds often exceeding standard purity levels and tailoring processes to client requirements.
- They are active in API development, including the preparation and filing of Drug Master Files (DMFs) in markets such as Brazil, China, Japan, the EU, the USA, Russia and others.
4. Flagship Product
- A standout in their portfolio is Loxoprofen Sodium Dihydrate, an API used for treating pain and inflammation (e.g., rheumatoid arthritis, post surgical pain, toothache). They are among the few manufacturers of this compound in India.
5. Robust Product Pipeline
- As of recent filings, Anlon maintains a diverse product pipeline with approximately 65 commercialized products, 28 at the pilot stage and 49 under development/testing.
Strategic Highlights & Growth Focus:
- Quality and Scale – With in house R&D, advanced manufacturing infrastructure and regulatory accreditations; they are positioned to deliver consistent quality and scale.
- Global Reach – Their exports span multiple continents, showcasing strong international traction and demand.
- Innovation & Differentiation – Custom manufacturing capabilities and strong compliance frameworks set them apart within the API sector.
What is Anlon Healthcare IPO issue open date?
The Anlon Healthcare Ltd IPO opens for subscription on Tuesday, 26 August 2025 and the issue remains open until Friday, 29 August 2025.
Price Band & Issue Size
- Price Band: ₹86 to ₹91 per equity share
- Total Fresh Issue Size: ₹121 crore for 1.33 crore shares
Lot Size & Minimum Investment
- Lot Size: 164 shares per lot.
- Minimum Investment (Retail Investor):
- At ₹86/share → ₹14,104 (1 lot)
- At ₹91/share → ₹14,924 (1 lot)
- Maximum Lots for Retail: Up to 13 lots (2,132 shares, approx ₹1.94 lakh)
Allocation of Shares
- Qualified Institutional Buyers (QIBs): Up to 75% of net issue
- Non Institutional Investors (NIIs): Up to 15%
- Retail Investors: Up to 10%
Timeline: Allotment, Refunds & Listing
- Allotment Finalisation Date: 1 September 2025
- Refunds Initiation: 2 September 2025
- Shares Credited to Demat / Listing Date: 3 September 2025 (on BSE & NSE)
Should you invest in Anlon Healthcare IPO?
Here’s a well rounded look at whether investing in the Anlon Healthcare IPO might make sense for you:
Market Sentiment & GMP
The Grey Market Premium (GMP) for Anlon Healthcare stands at approximately 6% above the upper price band (₹91), suggesting cautious optimism and modest listing expectations. However, some sources note that grey market activity is minimal or not yet observable, indicating early or neutral sentiment.
Company Fundamentals & Financials
- Strong financial growth: Revenue rose from ₹66.58 crore (FY24) to ₹120.29 crore (FY25), while profit after tax jumped from ₹9.65 crore to ₹20.52 crore.
- Healthy profitability metrics: ROCE at 21.9% and ROE at 40.5% are solid for this segment.
- Reasonable valuation: At ₹91/share, the IPO trades at a P/E of 23.6x, attractive compared to peers – Kronox (24.8x), AMI Organics (71.5x) and Supriya Lifesciences (29.2x).
- Strategic use of proceeds: Funds will support manufacturing expansion, working capital, debt repayment and other corporate needs.
- Regulatory positioning: Anlon has received several Drug Master File (DMF) approvals and adheres to global quality standards.
- Some risks remain: High dependence on a few key customers (top 10 contributed 75% of revenue) and historical operating cash flow weaknesses are concerning.
Conclusion
If you’re seeking medium to long term capital appreciation and trust in the pharmaceutical sector’s growth story, Anlon Healthcare’s IPO may be a decent addition especially given its improving financials, growth pipeline and reasonable valuation. That said, if you’re strictly looking for a short term listing pop, the modest GMP and analyst caution suggest tempered expectations. Balance expectations: Moderate listing gains possible, but main value may lie in long term execution and earnings growth.